MIND diet shows greater cognitive improvement in community-dwelling adults with high biomarker levels over three years

This randomized clinical trial investigated the impact of the MIND diet on cognitive trajectories in community-dwelling adults aged 65 to 84 years. Participants were initially free of cognitive impairment but exhibited varying levels of Alzheimer's disease biomarkers. The study followed 602 individuals over a period of three years to assess changes in global cognitive function. The primary objective was to determine whether adherence to the MIND diet could alter the rate of cognitive decline, particularly in those with higher baseline biomarker levels.

The intervention involved a specific dietary pattern rich in vegetables, berries, nuts, and whole grains, contrasted against a control diet with no specific restrictions. Researchers measured longitudinal changes in a global cognitive composite z-score, a metric that aggregates performance across multiple cognitive domains. The analysis focused on whether the dietary intervention could modify the slope of cognitive decline over time, specifically examining interactions with biomarker status.

Results indicated that participants in the MIND diet group experienced greater improvement in cognitive scores compared to the control group. This benefit was most pronounced among individuals with higher levels of amyloid-beta and p-tau181, key biomarkers associated with Alzheimer's pathology. The effect sizes were statistically significant, with 95% confidence intervals excluding the null value for both biomarkers. These findings suggest that dietary modification may be particularly effective for those with early biological changes indicative of neurodegenerative risk.

The study population consisted of older adults living in the community, which enhances the generalizability of the findings to real-world settings. The absence of reported adverse events or discontinuations suggests that the MIND diet is well-tolerated over extended periods. Safety profiles were monitored throughout the three-year follow-up, though specific details on adverse events were not detailed in the primary results. The tolerability of the dietary intervention appears consistent with previous literature on Mediterranean-style eating patterns.

Limitations of the study include the lack of reported data on specific adverse events and the absence of information regarding the setting of the trial. Additionally, the study did not report on secondary outcomes such as functional status or quality of life, which are often relevant to clinical practice. The causal inference is strengthened by the randomized design, but residual confounding cannot be entirely ruled out. The funding sources and potential conflicts of interest were not reported in the provided data.

For clinicians, these results offer a practical approach to managing cognitive risk in aging populations. The MIND diet represents a non-pharmacological intervention that could be integrated into comprehensive care plans for older adults. The practice relevance lies in the potential to delay cognitive decline through lifestyle modifications, especially for patients with identifiable biomarker risks. Future research should explore the mechanisms behind these benefits and investigate whether similar effects occur in populations with established cognitive impairment.